SPC
INTS icon

Sigma Planning Corp’s Intensity Therapeutics INTS Stock Holding History

Sigma Planning Corp’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,257
Closed -$23.1K – 1366
2025
Q4 		$23.1K Sell
2,257
-510
-18% -$5.17K ﹤0.01% 1287
2025
Q3 		$16.8K Hold
2,767
– – ﹤0.01% 1288
2025
Q2 		$21.2K Buy
2,767
+574
+26% +$11.8K ﹤0.01% 1240
2025
Q1 		$108K Hold
2,193
– – ﹤0.01% 1159
2024
Q4 		$96.5K Buy
2,193
+283
+15% +$20.5K ﹤0.01% 1128
2024
Q3 		$182K Sell
1,910
-5
-0.3% -$555 0.01% 1141
2024
Q2 		$235K Hold
1,915
– – 0.01% 1023
2024
Q1 		$249K Buy
1,915
+537
+39% +$64.4K 0.01% 1041
2023
Q4 		$295K Sell
1,378
-548
-28% -$57.7K 0.02% 625
2023
Q3 		$191K Buy
+1,926
New +$266K 0.01% 1101

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sigma Planning Corp's INTS Position: Q1 2026 in Review

Sigma Planning Corp sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 2,257 shares — an estimated $23.1K sold.

Sigma Planning Corp first reported a position in INTS in Q3 2023 and held it in 10 quarters. The position peaked at $295K in Q4 2023. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Sigma Planning Corp reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sigma Planning Corp sold 2,257 Intensity Therapeutics shares in Q1 2026, an estimated $23.1K.
  • Sigma Planning Corp first reported a position in Intensity Therapeutics in Q3 2023 and held it in 10 quarters.
  • Sigma Planning Corp's Intensity Therapeutics position peaked at $295K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.